BioCentury
ARTICLE | Clinical News

Tasimelteon: Development discontinued

February 4, 2013 8:00 AM UTC

Vanda discontinued development of tasimelteon to treat MDD after the double-blind, U.S. Phase IIb/III MAGELLAN trial in 507 patients with MDD showed that once-daily 20 mg tasimelteon missed the primary endpoint of reducing HAMD-17 scores from baseline to week 8 vs. placebo. Specifically, tasimelteon and placebo each reduced HAMD-17 scores by about 40% from baseline to week 8. Tasimelteon was well tolerated. ...